3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Adenomatous Polyposis Coli
2
Urinary Bladder Neoplasms
1
Precancerous Conditions
1
Glioma
1
Colorectal Neoplasms
1
Colonic Polyps
1
Carcinoma, Basal Cell
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Radiosurgery
23
Radiotherapy
20
Temozolomide
17
Lomustine
9
Bevacizumab
8
Surgical Procedures, Operative
7
Procarbazine
6
Vincristine
5
Nivolumab
5
Memantine
5
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Etoposide
4
Cisplatin
4
Carboplatin
4
Specimen Handling
3
Sodium Chloride
3
Radiation
3
Methylphenidate
3
Mental Status and Dementia Tests
3
Granulocyte Colony-Stimulating Factor
3
Gefitinib
3
Cyclophosphamide
3
Corticotropin-Releasing Hormone
3
Carmustine
3
icotinib
2
etoposide phosphate
2
efaproxiral
2
X-Rays
2
Tranexamic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Brain Neoplasms
×
Eflornithine
×
Clear all
NCT02796261
2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3
Unknown
343 enrolled